Cytokinetics, Incorporated (NASDAQ: CYTK) announced that its phase 3 clinical trial ACACIA-HCM met both primary endpoints for aficamten in patients ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE